U.S. Markets closed

Genfit SA (GNFT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.4700+0.0900 (+2.05%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.3800
Open4.2900
Bid4.1800 x 900
Ask4.5800 x 800
Day's Range4.2500 - 4.4700
52 Week Range3.6490 - 22.4800
Volume20,466
Avg. Volume62,356
Market Cap161.139M
Beta (5Y Monthly)0.84
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Genfit SA to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / September 30, 2020 / Genfit SA (NASDAQ:GNFT) will be discussing their earnings results in their 2020 First Half Earnings call to be held on September 30, 2020 at 4:30 PM Eastern Time.

  • GlobeNewswire

    GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

    * Innovative multi-biomarker blood test based on GENFIT’S NIS4™ technology is specifically designed to identify patients with at-risk non-alcoholic steatohepatitis (NASH) * LabCorp to commercialize the test for clinical care use in U.S. and Canada to help identify the approximately 10 million individuals at risk of progressing to late stage complications due to NASH among the tens of millions of people with metabolic risk factors and suspected disease * The test is expected to be available from LabCorp by early 2021       Lille, France; Cambridge, MA; [AND Burlington, N.C.,] September 28, 2020 GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, and LabCorp® (NYSE:LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, have agreed to a five-year exclusive licensing agreement for GENFIT’s NIS4™ technology to help identify patients with at-risk non-alcoholic steatohepatitis (NASH). As part of the agreement, LabCorp will develop and commercialize a blood-based molecular diagnostic test powered by NIS4™ technology throughout the U.S. and Canada enabling widespread access to healthcare providers.NASH remains a highly underdiagnosed disease due to its asymptomatic nature and the limitations of existing diagnostic approaches. Liver biopsy, a highly invasive procedure, is the current clinical standard to formally diagnose NASH and to determine the stage of fibrosis. NIS4™ technology, as recently published in The Lancet Gastroenterology & Hepatology (available here), is a novel, multi-biomarker-based algorithm specifically developed to identify at-risk NASH, defined as the presence of NASH based on a non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) ≥4 and significant to advanced fibrosis (F≥2). Patients with at-risk NASH have an advanced form of the disease and face a greater likelihood of progression to severe complications including liver cancer, cirrhosis and the need for liver transplant, if left untreated. A single test score generated from the integration of four independent biomarkers – miR-34a-5p, alpha-2-macroglobulin, YKL-40, and HbA1c – can be used by a healthcare provider to help inform the best course of intervention.  This agreement with LabCorp will provide broad clinical availability of the test to specialty and primary care physicians across the U.S. and Canada. LabCorp will leverage its deep experience in commercializing innovative diagnostics to educate providers on NASH and the importance of non-invasive testing. The collaboration between the organizations began in early 2019, when LabCorp began offering NIS4™ technology to biopharmaceutical customers for use in clinical studies through Covance, its drug development business. Marcia Eisenberg, Ph.D., Chief Scientific Officer of LabCorp Diagnostics, stated: “LabCorp is committed to developing and distributing novel diagnostics to support the diagnosis of patients with NASH, which is one of the fastest growing serious medical conditions in the U.S. GENFIT’s NIS4™ is a non-invasive technology specifically designed to identify patients with both NASH and significant to advanced fibrosis, and is an important advance in the ability to identify patients with NASH. We have gained valuable experience with this test since we began performing it in 2019 for clinical studies with biopharmaceutical clients, which will provide insights as we develop and prepare to make it available for use in patient care.” Suneil Hosmane, Ph.D., Head of Global Diagnostics at GENFIT added: “We are pleased to expand our collaboration with LabCorp and are very enthusiastic about the potential impact of this agreement. We strongly believe that this test will help healthcare providers identify the approximately 10 million patients with at-risk NASH and higher risk of progression among the tens of millions with metabolic risk factors, such as type 2 diabetes and obesity, and suspected disease.” Pascal Prigent, CEO of GENFIT, continued, “This partnership supports GENFIT’s pioneering research efforts in the field of NASH diagnostics that were recently recognized by experts in our most recent Lancet publication. The commercialization of NIS4™ technology by LabCorp is a defining opportunity whereby millions of NASH patients can become aware of, and then begin to take control of their disease.”GENFIT is a pioneer in NASH diagnostics and is committed to the development of additional diagnostics and therapeutics in chronic liver disease. LabCorp has been involved in the development of drugs and diagnostics for more than 50 years and is a recognized global leader in NASH clinical trials. Specific financial terms for this agreement have not been disclosed. ABOUT NIS4™NIS4™ is GENFIT’s non-invasive, blood-based diagnostic technology, which was developed to identify patients with non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis (F>2), also referred to as at-risk NASH. In January 2019, GENFIT signed a licensing agreement with LabCorp® to make NIS4™ technology available for use in clinical research through their drug development subsidiary, Covance. GENFIT also continues to explore opportunities to obtain formal marketing authorization of an in vitro diagnostic (IVD) version of NIS4™ in both the U.S. and European markets. For more information, please visit: https://nis4.com.ABOUT GENFITGENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT initiated a Phase 3 clinical trial of elafibranor in patients with primary biliary cholangitis (PBC). As part of GENFIT’s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4™, a new, non-invasive blood-based diagnostic technology which, if approved, could enable easier identification of patients with at-risk NASH. With facilities in Lille and Paris, France, and Cambridge, MA, USA, the Company has approximately 200 employees. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com FORWARD LOOKING STATEMENTSThis press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995, with respect to GENFIT, including statements about NIS4™’s performance in identifying patients with at-risk NASH, the performance of NIS4™ relative to other technologies, the potential for diagnostic tests powered by NIS4™ technology to play a critical role in the diagnosis and management of patients with NASH, the potential for non-invasive testing to gain importance, its capability to identify patients who may require medical intervention, the development plans for NIS4™ in the U.S. and in Europe and timing of such development plans, and the potential to obtain formal marketing authorization of an IVD version of NIS4™ in the U.S. and/or European markets.   The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements.  Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates and the Company’s continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the French Autorité des marchés financiers (“AMF”), including those listed in Section 2.1 “Main Risks and Uncertainties” of the Company’s 2019 Universal Registration Document filed with the AMF on May 27, 2020 under n° D.20-0503, which is available on GENFIT’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s 20-F dated May 27, 2020. In addition, even if the Company’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods.  These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. ABOUT LABCORPLabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostics solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11.5 billion in 2019.To learn more about LabCorp, visit www.LabCorp.com, and to learn more about LabCorp’s Covance Drug Development business, visit www.Covance.com.LABCORP FORWARD-LOOKING STATEMENTSThis press release contains forward-looking statements, including but not limited to statements with respect to clinical laboratory testing, including a testing in development based on GENFIT’s NIS4™ technology, the impact of various factors on operating and financial results, and the opportunities for future growth. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, the Company’s satisfaction of regulatory and other requirements, patient safety issues, changes in testing guidelines or recommendations, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, and employee relations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.GENFIT CONTACTGENFIT | InvestorsNaomi EICHENBAUM – Investor Relations | Tel: +1 (617) 714 5252 | investors@genfit.comPRESS RELATIONS | MediaHélène LAVIN – Press Relations | Tel: +3 33 2016 4000 | Helene.lavin@genfit.comLABCORP CONTACTS Clarissa Willett – Investors | Tel: +1 (336) 436 5076 | Investor@LabCorp.comDonald Von Hagen – Media | Tel: +1 (336) 436 8263 | Media@LabCorp.com  GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com         Attachment * GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

  • The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs
    Benzinga

    The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 24) * Beigene Ltd (NASDAQ: BGNE)) * Forte Biosciences Inc (NASDAQ: FBRX) * Pacific Biosciences of California Inc (NASDAQ: PACB)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 24) * ADiTx Therapeutics Inc (NASDAQ: ADTX) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Akebia Therapeutics Inc (NASDAQ: AKBA) * Alector Inc (NASDAQ: ALEC) * AnPac Bio-Medical Science Co Ltd - ADR (NASDAQ: ANPC) * Amarin Corporation plc (NASDAQ: AMRN) * Athira Pharma Inc (NASDAQ: ATHA) * BELLUS Health Inc (NASDAQ: BLU) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) * DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT) * Evofem Biosciences Inc (NASDAQ: EVFM) * Fusion Pharmaceuticals Inc (NASDAQ: FUSN) * Genetron Holdings Ltd - ADR (NASDAQ: GTH) * Genfit SA (NASDAQ: GNFT) * Gritstone Oncology Inc (NASDAQ: GRTS) * Happiness Biotech Group Ltd (NASDAQ: HAPP) * Histogen Inc (NASDAQ: HSTO) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * Jaguar Health Inc (NASDAQ: JAGX) * Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) * Natus Medical Inc (NASDAQ: NTUS) * Neos Therapeutics Inc (NASDAQ: NEOS) * Neurobo Pharmaceuticals Inc (NASDAQ: NRBO) * NextCure Inc (NASDAQ: NXTC) * Odonate Therapeutics Inc (NASDAQ: ODT) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * PainReform Ltd (NASDAQ: PRFX) * Pandion Therapeutics Inc (NASDAQ: PAND) * Pliant Therapeutics Inc (NASDAQ: PLRX) * Psychemedics Corp. (NASDAQ: PMD) * RA Medical Systems Inc (NYSE: RMED) * Renalytix AI PLC (NASDAQ: RNLX) * Rockwell Medical Inc (NASDAQ: RMTI) * Satsuma Pharmaceuticals Inc (NASDAQ: STSA) * SCYNEXIS Inc (NASDAQ: SCYX) * Solid Biosciences Inc (NASDAQ: SLDB) * Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) * Teligent Inc (NEW JERSEY) (NASDAQ: TLGT) * Theravance Biopharma Inc (NASDAQ: TBPH) * Tricida Inc (NASDAQ: TCDA) * Vaccinex Inc (NASDAQ: VCNX) * Viveve Medical Inc (NASDAQ: VIVE) * Taro Pharmaceutical Industries Ltd. (NYSE: TARO)Stocks In Focus Novavax Commences Phase 3 Study of Coronavirus Vaccine Candidate Novavax, Inc. (NASDAQ: NVAX) said it has initiated its first Phase 3 study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, its COVID-19 vaccine candidate.The trial is being conducted in the U.K. in partnership with the UK Government's Vaccines Taskforce, and is expected to enroll and immunize up to 10,000 individuals, ages 18-84 years, with and without relevant comorbidities, over the next four to six weeks, Novavax said.Separately, Endo International PLC (NASDAQ: ENDP) announced a non-exclusive agreement with Novavax to provide fill-finish manufacturing services at its plant in Rochester, Michigan for NVX-CoV2373.In pre-market trading Friday, Novavax shares were up 7.48% to $110.10, and Endo was gaining 9.27% to $3.30.Altimmune Rallies On Institutional Buying Altimmune Inc (NASDAQ: ALT) shares moved after a filing by the company revealed D.E. Shaw and D.E. Shaw & Co. each beneficially own 1,634,730 shares, or 5% stake in the company.The stock rallied 8.89% to $13.10 in after-hours trading.Clover Biopharma Announces Positive Preliminary Phase 1 Results From Coronavirus Vaccine Program Clover Biopharma, which is developing a protein-based COVID-19 S-Trimer vaccine candidate in combination with adjuvants from GlaxoSmithKline plc (NYSE: GSK) or Dynavax Technologies Corporation (NASDAQ: DVAX) said the investigational vaccine induced a strong immune response and protection against SARS-CoV-2 in animal models.Clover also announced preliminary results from a Phase 1 study showing that the vaccine is likely to be safe and well-tolerated, with high levels of neutralizing antibodies.Based on these preliminary results, an additional 200 participants will be enrolled in a Phase 1 dose-expansion study at the selected S-Trimer dose-level and adjuvanted with either GSK's pandemic adjuvant or Dynavax's advanced adjuvant CpG 1018 plus alum, the company said.Clover also said it plans to initiate a Phase 2/3 efficacy study before the end of 2020.Genfit Announces First Patient Visit In Pivotal Phase 3 Study of Elafibranor In Primary Biliary Cholangitis Genfit announced the first patient first visit for ELATIVE, its global, pivotal, Phase 3 study evaluating the efficacy and safety of elafibranor in primary biliary cholangitis, or PBC."This is a significant milestone and it means that we are now a step closer to hopefully bringing patients and caregivers a promising option to treat this debilitating disease and its symptoms. We see an important potential for elafibranor in PBC and will provide further information at the upcoming Corporate Update on September 30" said Pascal Prigent, CEO at GENFIT.In after-hours trading, the stock jumped 13.08% to $4.15.Radius Health, Partner Say Enrollment Into Phase 3 Study of Breast Cancer Drug Completed Radius Health Inc (NASDAQ: RDUS) and partner Menarini Group said the target enrollment milestone has been reached in the Phase 3 EMERALD clinical trial of elacestrant that is being studied in postmenopausal women and men with ER+/HER2- advanced or metastatic breast cancer.The companies expect to conduct primary analysis of data from the study in the second half of 2021. An independent data monitoring committee that reviewed results of futility analysis conducted after the completion of 70% of targeted enrollment recommended that the study proceed without modification, the companies said.Marinus Cleared to Initiate Registrational Phase 3 Study of Ganaxolone In Refractory Status Epilepticus Marinus Pharmaceuticals Inc (NASDAQ: MRNS) said it has satisfied the FDA's protocol-specific questions for the registrational Phase 3 trial of intravenous ganaxolone in refractory status epilepticus, allowing enrollment to begin in this clinical trial. The company expects the first patient to be enrolled in October and release topline data in the first half of 2022.Marinus recently reported positive Phase 3 results for ganaxolone in CDKL5 deficiency disorderIn pre-market trading, the stock was adding 5.61% to $11.30.On The Radar IPOs Prelude Therapeutics, a clinical-stage precision oncology company, priced its initial public offering, or IPO, of 8.325 million shares at $19 per share, the upper end of the estimated price range of $17-$19. Gross proceeds from the offering are expected at $158.2 million. The shares will begin trading on the Nasdaq under the ticker symbol PRLD.Greenwich LifeSciences Inc., a clinical-stage biopharma focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, priced its IPO of 1.261 million shares at $5.75 apiece, for raising gross proceeds of $7.25 million. The shares will begin trading on the Nasdaq under the symbol GLSI.MV Pharmaceuticals, Inc., a precision oncology company, priced its IPO of 11.765 million shares at $18 per share. The shares are expected to begin trading on the Nasdaq under the ticker symbol PMVP.See more from Benzinga * The Daily Biotech Pulse: Gilead's .25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO * The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma * The Daily Biotech Pulse: Legal Relief For Evolus, Fulgent to Join S&P SmallCap 600, AIM ImmunoTech's Positive Cancer Drug Readout(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.